
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/glycosaminoglycan-therapy-for-bladder-diseases-22 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:03:38 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Glycosaminoglycan Therapy for Bladder Diseases | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Glycosaminoglycan Therapy for Bladder Diseases"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/glycosaminoglycan-therapy-for-bladder-diseases-22"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/22/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Glycosaminoglycan Therapy for Bladder Diseases"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/22/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../../covid-19.hbs.hu/index.html" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/222679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Glycosaminoglycan Therapy for Bladder Diseases</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1384</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="22">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="22">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/UAI"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Glycosaminoglycan%20Therapy%20for%20Bladder%20Diseases&amp;url=https://hbs.hu/r/UAI"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/UAI&amp;title=Glycosaminoglycan%20Therapy%20for%20Bladder%20Diseases&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/UAI"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="glycosaminoglycan-therapy-for-bladder-diseases-22.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/glycosaminoglycan-therapy-for-bladder-diseases-22"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/22?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="22" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>4.   </p>
                                        
                                            <p>15. This reprint is offered to you courtesy of IBSA Ins titut Biochimique SA </p>
                                        
                                            <p>13. [29] Parsons CL. The role of the urinary epithelium in the pathog enesis of interstitial cystitis/prostatitis/urethritis. Urolo gy 2007;69: 9–16. [30] Bassi PF. Insights on clinical use of Ialuril 1 . Presentation at: 26th Annual European Association of Urology Congress; March 18–21. Vienna, Austria, 2011. [31] Parsons CL. A model for the function of glycosaminoglycans in the urinary tract. World J Urol 1994;12:38–42. [32] Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 2011;59:645–51, Corrigendum. Eur Urol 2011;60:193. [33] McLean RJ, Nickel JC. Glycosaminoglycans and struvite calculi. World J Urol 1994;12:49–51. [34] Siracusano S, Cucchi A, Ciciliato S, Lampropoulou N, Vittur F. Urinary levels of glycosaminoglycans in patients with idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2009; 20:1477–80. [35] Chen SC, Henry DO, Hicks DG, Reczek PR, Wong MK. Intravesical administration of plasminogen activator inhibitor type-1 inhibits in vivo bladder tumor invasion and progression. J Urol 2009;181: 336–42. [36] Huygens A, Crnolatac I, Maes J, et al. Influence of the glycosamino- glycan layer on the permeation of hypericin in rat bladders in vivo. BJU Int 2007;100:1176–81. [37] Foley S. Management of bladder dysfunctions in UK: Ialuril 1 in clinical practice. Presentation at: 26th Annual European Associa- tion of Urology Congress; March 18–21. Vienna, Austria, 2011. E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 459 </p>
                                        
                                            <p>3. This reprint is offered to you courtesy of IBSA Ins titut Biochimique SA Glycosaminoglycan Therapy for Bladder Diseases: Emerging New Treatments Authors: Pier Francesco Bassi, Elisabetta  Costantini, Steve  Foley, Stefano Palea reprinted from Special EAU Vienna Compilation Edition European Urology Supplements, Volume 10, Issue 6 </p>
                                        
                                            <p>12. to 16.2, nocturia from 4.5 to 2.8 voids per night, and frequency from 15 to 9.5 voids/d [37] . The treatment was easy to administer, and considering both groups were difficult-to-treat patient populations, the results were regarded as promising and need confirming in larger and longer-term controlled studies [37] . 6.    Conclusions Robust evidence indicates that a defective urothelial barrier may underlie or be involved in the pathogenesis of several chronic bladder conditions, such as IC/PBS, recurrent UTIs, overactive bladder, chemical and radiation cystitis, and urothelial cancer. Promising preliminary studies of the intravesical instillation of HA-CS as GAG replacement therapy suggest that this formulation has efficacy potential in a wide range of clinical applications. Conflicts of interest The authors have nothing to disclose. Funding support IBSA supported the animal model study presented by Stefano Palea through a scientific grant as well as medical writing and editorial assistance for this article. Acknowledgments The authors would like to thank inScience Communications for medical writing and editorial assistance in the prepara- tion of this article for publication. References [1] Fall M, Oberpenning F, Peeker R. Treatment of bladder pain syn- drome/interstitial cystitis 2008: can we make evidence-based deci- sions? Eur Urol 2008;54:65–78. [2] Cervigni M, Natale F, Nasta L, Padoa A, Voi RL, Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for re- fractory painful bladder syndrome/interstitial cystitis. Int Urogy- necol J Pelvic Floor Dysfunct 2008;19:943–7. [3] Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007;51:1534–41, discussion 1540–1. [4] Parsons CL. The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain. BJU Int 2011;107:370–5. [5] Costantini E. The role of the urinary epithelium. Presentation at: 26th Annual European Association of Urology Congress; March 18–21. Vienna, Austria, 2011. [6] Riedl CR, Engelhardt PF, Daha KL, et al. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:717–21. [7] Marchand JE, Sant GR, Kream RM. Increased expression of sub- stance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis. Br J Urol 1998;81:224–8. [8] Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urol- ogy 2007;69:34–40. [9] Hurst RE, Parsons CL, Roy JB, Young JL. Urinary glycosaminoglycan excretion as a laboratory marker in the diagnosis of interstitial cystitis. J Urol 1993;149:31–5. [10] Keay S, Warren JW, Zhang CO, et al. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients. J Urol 1999;162:1487–9. [11] Keay S, Zhang CO, Marvel R, Chai T. Antiproliferative factor, hepa- rin-binding epidermal growth factor-like growth factor, and epi- dermal growth factor: sensitive and specific urine markers for interstitial cystitis. Urology 2001;57(Suppl 1):104. [12] Rastogi P, Rickard A, Dorokhov N, Klumpp DJ, McHowat J. Loss of prostaglandinE2releasefromimmortalizedurothelialcellsobtained from interstitial cystitis patient bladders. Am J Physiol Renal Physiol 2008;294:F1129–35. [13] Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 1997;49:52–7. [14] Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Ann Intern Med 2001;134:868–81. [15] Clauw DJ. The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia. Med Hypotheses 1995;44: 369–78. [16] Sand PK. Proposed pathogenesis of painful bladder syndrome/in- terstitial cystitis. J Reprod Med 2006;51:234–40. [17] Sant GR. Etiology, pathogenesis, and diagnosis of interstitial cysti- tis. Rev Urol 2002;4(Suppl 1):S9–15. [18] van de Merwe JP, Nordling J, Bouchelouche P, et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol 2008; 53:60–7. [19] Wesselmann U. Interstitial cystitis: a chronic visceral pain syn- drome. Urology 2001;57(Suppl 1):32–9. [20] Jasmin L, Janni G, Manz HJ, Rabkin SD. Activation for CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. J Neurosci 1998;18:10016–29. [21] Nazif O, Teichman JM, Gebhart GF. Neural upregulation in intersti- tial cystitis. Urology 2007;69:24–33. [22] Chuang YC, Chancellor MB, Seki S, et al. Intravesical protamine sulfate and potassium chloride as a model for bladder hyperactivi- ty. Urology 2003;61:664–70. [23] Parsons CL. Prostatitis, interstitial cystitis, chronic pelvic pain, and urethral syndrome share a common pathophysiology: lower uri- nary dysfunctional epithelium and potassium recycling. Urology 2003;62:976–82. [24] Sag  ̆ lam B, Cikler E, Zeybek A, C ̧ etinel S, Ercan F, S ̧ ener G. Protective effects of 2-mercaptoethane sulfonate (mesna) on protamine sul- fate induced bladder damage. Marmara Med J 2005;18:6–12. [25] Palea S. Experimental effects of sodium hyaluronate and chondroi- tin sulfate combination in a bladder model. Presentation at: 26th Annual European Association of Urology Congress; March 18–21. Vienna, Austria, 2011. [26] Fu  ̈ llhase C, Soler F, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial ure- thral obstruction. J Urol 2010;184:783–9. [27] De Laet K, DeWachter S, Wyndaele J-J. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neu- rourol Urodyn 2006;25:156–61. [28] Yamaguchi O. Antimuscarinics and overactive bladder: other mech- anism of action. Neurourol Urodyn 2010;29:112–5. E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 458 </p>
                                        
                                            <p>14. © 2011 European Association of Urology. Published b y Elsevier B.V. All rights reserved. This journal and the individual contributions conta ined in it are protected under copyright by the Euro pean Association of Urology and the following terms and conditions apply to the ir use: Photocopying Single photocopies of single articles may be made f or personal use as allowed by national copyright la ws. Permission of the Publisher and payment of a fee is required for all other phot ocopying, including multiple or systematic copying,  copying for advertising or  promotional purposes, resale, and all forms of docu ment delivery. Special rates are available for educ ational institutions that wish to make photocopies for non-profit educational classroo m use. For information on how to seek permission visit www. elsevier.com/permissions or call: (+44) 1865 843830  (UK) / (+1) 215 239 3804 (USA). Derivative works Subscribers may reproduce tables of contents or pre pare lists of articles including abstracts for inte rnal circulation within their  institutions. Permission of the Publisher is requir ed for resale or distribution outside the instituti on. Permission of the Publisher is required for all other derivative works, including c ompilations and translations (please consult www.el sevier.com/permissions).  Electronic storage or usage Permission of the Publisher is required to store or  use electronically any material contained in this  journal, including any article or part of an article (please consult www.elsevier.com/ permissions). Except as outlined above, no part of this publicati on may be reproduced, stored in a retrieval system  or transmitted in any form or by any means, electronic, mechanical, photocopying,  recording or otherwise, without prior written perm ission of the Publisher. Notice No responsibility is assumed by the Publisher for a ny injury and/or damage to persons or property as a  matter of products liability, negligence or otherwise, or from any use or operati on of any methods, products, instructions or ideas  contained in the material  herein. Because of rapid advances in the medical sc iences, in particular, independent verification of d iagnoses and drug dosages should be made. Although all advertising material is expected to co nform to ethical (medical) standards, inclusion in  this publication does not  constitute a guarantee or endorsement of the qualit y or value of such product or of the claims made of  it by its manufacturer. Advertising information: Advertising orders and enquiries can be sent to:  USA, Canada and South America: Mr Tino DeCarlo, Advertising Department, Elsevier Inc., 360 Park Aven ue South, New York, NY 10010-1710, USA; phone: (+1)  (212) 633 3815; fax: (+1) (212) 633 3820; e-mail: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="15613b7170767467797a5570796670637c70">[email&#160;protected]</a> r.com.  Europe  and  ROW: Advertising Sales: Elsevier Pharma Solutions, 32  Jamestown  Road,  London  NW1  7BY,  UK;  phone:  (+44)   (0)  20  7424  4259;  fax:  (+44)  (0)  20  7424  4433;  e-m ail: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="8ce9e0ffe9fae5e9fefce4edfee1eda2f9e7cce9e0ffe9fae5e9fea2efe3e1a2">[email&#160;protected]</a> Commercial Reprint Sa les, Greg Davies, Elsevier Ltd.; phone: (+44) 20 74 24 4422; fax: (+44) 20 7424 4433; e-mail: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="b2d5c09cd6d3c4dbd7c1f2d7dec1d7c4dbd7c09cd1dddf9c">[email&#160;protected]</a> The paper used in this publication meets the requir ements of ANSI/NISO Z39.48-1992 (Permanence of Pape r). Abstracted/indexed  in:  ADONIS, BIOBASE, Current Awareness in Biological Sc iences, EMBASE, Medical Documentation Service, Research Alert, Science Citation Index, Sc isearch, SCOPUS, SIIC Data Bases, Uroline Printed by Henry Ling Ltd, Dorchester, Dorset, UK </p>
                                        
                                            <p>1. Volume 10   Issue 6   October 2011      ISSN 1569-9056 EU-ACME accredited content Special EAU Vienna Compilation Edition Guest Editor: Francesco Montorsi, Milan, Italy E u r o p e a n   U r o l o g y   “ Y ou r ” Pl a t i nu m Jo u r n a l EUROPEAN UROLOGY SUPPLEMENTS Glycosaminoglycan Therapy for Bladder Diseases:  Emerging New Treatments Pier Francesco Bassi, Elisabetta Costantini, Steve  Foley, Stefano Palea  R EPRINTEDFROM V OLUME 10, I SSUE 6, 2011 </p>
                                        
                                            <p>9. 5.1.    Recurrent urinary tract infections Entry of microorganisms (eg, Escherichia coli ) that are able to invade urothelial cells left vulnerable by increased perme- ability or other deficiency provides a protected niche for the infection to progress [31] . In line with this, and the idea of exogenous GAGs as important in treating bladder infection, Damiano et al conducted a well-controlled clinical trial of intravesical HA-CS in patients with recurrent UTIs [32] . The randomized double-blind, placebo-controlled study enrolled 57 women with recurrent UTIs (defined as three or more episodes of uncomplicated infection [ &gt; 10 3 CFU/ml of [(Fig._2)TD$FIG] Fig. 2 – Urinary function results: bladder capacity (BC), threshold pressure (ThP), micturition pressure (MP), and bladder compliance with instillations of sodium hyaluronate–chondroitin sulfate (HA-CS) in the rat bladder model [25] . ANOVA = analysis of variance; KCl = potassium chloride; NaCl = sodium chloride; PS = protamine sulfate. [(Fig._3)TD$FIG] Fig. 3 – Kaplan-Meier plot of time to recurrence of infection in patients with recurrent urinary tract infections receiving intravesical sodium hyaluronate– chondroitin sulfate (HA/CS) or placebo. Reproduced with permission from Elsevier [32] . E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 455 </p>
                                        
                                            <p>2. EDITOR EMERITUS (1975–2005) Claude Schulman, Belgium EUROPEAN UROLOGY EDITORIAL OFFICE Università Vita Salute San Raffaele Via Stamira d’Ancona 20 20127 Milan, Italy Tel: +39 02 2643 6438; Fax: +39 02 2643 6450 E-mail: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="60100c0114090e150d200515120f1005010e15120f0c0f07194e030f0d">[email&#160;protected]</a> Official Journal of  Societa` Italiana di Urologia (SIU) Official Journal of the EDITOR-IN-CHIEF Francesco Montorsi, Italy ASSOCIATE EDITORS EDITORIAL ASSISTANTS EDITORIAL BOARD Anders Bjartell, Sweden James Catto, UK Christian Stief, Germany Christian Gratzke, Germany Tullio Sulser, Switzerland Giacomo Novara, Italy Alexandre Zlotta, Canada Shahrokh Shariat, USA EAU-EBU UPDATE SERIES EDITOR Oliver W. Hakenberg, Germany NORTH AMERICAN EDITORS Stephen Freedland, USA Inderbir Gill, USA STATISTICAL EDITOR Richard Sylvester, Belgium COPY EDITOR Samantha Enslen  Dragonfly Editorial, USA EDITORIAL OFFICE MANAGER Cathy Pierce, Italy EDITORIAL OFFICE ASSISTANT Sinéad O’Sullivan, Italy Patricia Bachmann, Switzerland                            Judith Carlen, Germany                                           B eth Roby, USA Peter Albers, Germany Peter Albertsen, USA Gerasimos Alivizatos, Greece Karl-Erik Andersson, Sweden Apostolos Apostolidis, Greece Riccardo Autorino, Italy Marko Babjuk, Czech Republic Alexander Bachmann, Switzerland Rafael Badalyan, Armenia Riccardo Bartoletti, Italy Patrick Bastian, Germany Ricarda Bauer, Germany Michael Blute, USA Alberto Briganti, Italy Lukas Bubendorf, Switzerland Umberto Capitanio, Italy Rufus Cartwright, UK Andrea Cestari, Italy Christopher Chapple, UK Joseph Chin, Canada Stefano Ciatto, Italy Noel Clarke, UK Laurence Collette, Belgium Renzo Colombo, Italy Elisabetta Costantini, Italy Francisco Cruz, Portugal Guido Dalbagni, USA Rocco Damiano, Italy Friouz Daneshgari, USA Jean de la Rosette, Netherlands Theo de Reijke, Netherlands John Denstedt, Canada Roger Dmochowski, USA James Eastham, USA Christopher Eden, UK Shin Egawa, Japan Scott Eggener, USA Jack Elder, USA Abdullah Erdem Canda, Turkey Vincenzo Ficarra, Italy Paolo Fornara, Germany Clare Fowler, UK John Gearhart, USA Matthew Gettman, USA Gianluca Giannarini, Italy Ofer Gofrit, Israel Christian Gozzi, Germany Stavros Gravas, Greece Francesco Greco, Germany Ju  rgen Gschwend, Germany Bertrand Guillonneau, USA Axel Haferkamp, Germany Axel Heidenreich, Germany Harry Herr, USA Piet Hoebeke, Belgium Brant Inman, USA Jacques Irani, France Kazuto Ito, Japan Ates ̧ Kadiog ̆ lu, Turkey Pierre Karakiewicz, Canada Michael Kattan, USA Ziya Kirkali, USA Eric Klein, USA Pilar Laguna, Netherlands Massimo Lazzeri, Italy Eric Lechevallier, France Evangelos Liatsikos, Greece Stephan Madersbacher, Austria Massimo Maffezzini, Italy Padraig Malone, UK Luis Martínez-Piñeiro, Spain Martin Michel, Netherlands Andrea Minervini, Italy Rodolfo Montironi, Italy Masaru Murai, Japan Declan Murphy, Australia Richard Naspro, Italy Willem Oosterlinck, Belgium Jean-Jacques Patard, France Anup Patel, UK Jehonathan Pinthus, Canada Francesco Porpiglia, Italy David Ralph, UK Jens Rassweiler, Germany Oliver Reich, Germany Andrea Salonia, Italy Christian Saussine, France Vincenzo Scattoni, Italy Jack Schalken, Netherlands Michael Seitz, Germany Arnulf Stenzl, Germany Cora Sternberg, Italy Jens-Uwe Stolzenburg, Germany Urs Studer, Switzerland Nazareno Suardi, Italy George Thalmann, Switzerland Houston Thompson, USA Bertrand Tombal, Belgium Karim Touijer, USA Levent Tu  rkeri, Turkey Theo van der Kwast, Canada Henk Van der Poel, Netherlands Hendrik Van Poppel, Belgium Bas van Rhijn, Netherlands Yoram Vardi, Israel Johannes Witjes, Netherlands Wim Witjes, Netherlands Jean-Jacques Wyndaele, Belgium Ofer Yossepowitch, Israel Richard Zigeuner, Austria Amnon Zisman, Israel </p>
                                        
                                            <p>5. Glycosaminoglycan Therapy for Bladder Diseases: Emerging New Treatments Pier Francesco Bassi a , Elisabetta Costantini b , * , Steve Foley c , Stefano Palea d a Department of Urology, Catholic University School of Medicine, Rome, Italy b Urology Department, University of Perugia, Perugia, Italy c Royal Berkshire County Hospital, Reading, UK d Urosphere S.A.S., Toulouse, France E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 a v a i l a b l e  a t  w w w . s c i e n c e d i r e c t . c o m j o u r n a l  h o m e p a g e :  w w w . e u r o p e a n u r o l o g y . c o m Article info Keywords: Chronic cystitis Ialuril Intravesical instillation Painful bladder syndrome Sodium hyaluronate/chondroitin sulfate Abstract Damage to the urothelial gycosaminoglycan (GAG) barrier layer is thought to underlie the pathogenesis of several chronic bladder pathologies, including inter- stitial cystitis/painful bladder syndrome (IC/PBS), chemical or radiation cystitis, and recurrent urinary tract infections (UTIs). Penetration of urinary constituents into the bladder wall causes C-fiber activation, mast cell activation, and histamine release. The resulting smooth muscle contraction, neurogenic inflammation, and hypersensitivity translate into the urinary urgency and frequency and chronic pelvic pain that are characteristic symptoms of several chronic bladder conditions. Protecting the urothelium or promptly restoring the GAG layer to prevent the cycle of inflammation and hypersensitization is the basis for the clinical use of intra- vesical instillations of sodium hyaluronate–chondroitin sulfate (HA-CS; Ialuril 1 ; IBSA Institut Biochimique SA, Lugano, Switzerland). In an experimental animal model, HA-CS instillations counteracted the increase of micturition frequency and threshold pressure, and they increased the bladder compliance, following urothelial damage induced by protamine sulfate and potas- sium chloride. In the clinical setting, patients with IC/PBS receiving intravesical HA-CS experienced significantly fewer micturitions, increased voiding volumes, symptomatic improvement with respect to pain and urgency/frequency symptom scores, and improved quality of life. In patients with recurrent UTIs, urinary intravesical HA-CS prompted an almost 90% reduction of episodes per patient per year versus 10% in the control group and, compared with the control group, patients in the HA-CS group lasted 3.5-fold longer between episodes. The potential role of intravesical HA-CS as GAG replacement therapy in other chronic and challenging bladder conditions, including overactive bladder, calculi, and urothelial cancer, is being investigated. Urothelial damage is the central theme of many chronic bladder pathologies. Intravesical instillation of the sodium hyaluronate 1.6%–chondroitin sulfate 2% combination has proved to be a useful treatment approach for the protection and replacement of this GAG barrier layer. # 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Department of Medical-Surgical Specialties and Public Health, Section of Urology and Andrology, Via Brunamonti 51, 06100 Perugia, Italy. Tel. +39 075 5783198; Fax: +39 075 5726123. E-mail address: <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="2e4b4d415d5a4f405a6e5b40475e4900475a">[email&#160;protected]</a> (E. Costantini). 1569-9056/$ – see front matter # 2011 European Association of Urology. Published by Elsevier B.V. All rights reserved.  doi: 10.1016/j.eursup.2011.06.001 </p>
                                        
                                            <p>11. to directly inhibit the formation of calculi by inhibiting nucleation, crystal growth, and their agglomeration [33] . 5.4.    Chemical cystitis More than half of patients undergoing intravesical chemo- therapy with agents such as epirubicin, mitomycin C, and thiotepa are reported to experience cystitis. This chemically induced inflammation is another potential therapeutic target for intravesical HA-CS. Providing a protective layer prophylatically may mean that patients would be better able to tolerate chemotherapy and complete the required course of therapy [30] . 5.5.    Overactive bladder Overactive bladder is another bladder dysfunction that may benefit from GAG replacement therapy with HA-CS. It has recently been shown that the urine of patients with bladder hyperactivity (detrusor overactivity) contained a lower concentration of GAGs than healthy patients in the control group [34] , which may explain the efficacy of HA-CS in patients with this condition, possibly by improving the integrity of the urothelial GAG layer and thus reducing micturition frequency. 5.6.    Urothelial cancer There is evidence that the implantation and seeding of viable tumor cells influences bladder cancer recurrence [35] , and endeavoring to prevent early implantation would appear to be a worthwhile therapeutic focus. The current clinical approach involves chemotherapy with instillations of cytotoxic agents, and two recent proposals under investigation describe an antiadhesive application [36] and an antiangiogenic strategy. Providing a more protective barrier or bolstering the GAG layer of the urothelium to prevent implantation of tumor cells is another option with therapeutic potential in recurrent bladder cancer [30] . The concept of GAG involvement as the basis of many pathologic bladder conditions has not only inspired a new treatment but has modified the clinical concept of bladder disease and the approaches to the resolution of these chronic and challenging conditions [4,30] . 5.7.    Sodium hyaluronate–chondroitin sulfate: clinical use in a UK hospital practice setting The incidence of bacterial cystitis in the United Kingdom is estimated to be 3% of the population. Although current data onrecurrentinfectionsare limited, ithas beensuggestedthat approximately 1 in 4 of those individuals will have a recurrence within 6 mo, and of those, 1 in 10 will have a third infection [37] . The standard treatment strategy for bacterial cystitis in the United Kingdom includes lifestyle changes, postcoital antibiotics, and low-dose antibiotic prophylaxis [37] . Another bladder condition considered problematic in the United Kingdom is IC/PBS. Although statistics are lacking, it is estimated to affect nearly 200 000 individuals, and the number of patients requiring attention and treatment for this condition in a large district general hospital in Reading, near London, could amount to nearly 2000 patients [37] . Lack of awareness and the often obscure nature of the condition contribute to the delay in diagnosis and treatment, which is estimated to be up to 4 yr. Following lifestyle modifications and conventional and alternative treatments, the general hospital in Reading has also used intravesical therapies for this condition. Although single agent sodium hyaluronate has been a popular and useful treatment, a consultant in a large district general hospital near London reports there is room for improvement in the intravesical treatment of patients with IC/PBS [37] . The following series of patients received the combina- tion of HA-CS, which has recently become available for intravesical treatment at the hospital [37] . A group of 30 patients received HA-CS for recurrent UTIs or IC/PBS, after providing full written permission for treatment. The first course of HA-CS was administered weekly for 4 wk, then biweekly for 1 mo (6 units). Maintenance treatment was one instillation per month, and patients were taught to self- treat where possible [37] . Of the 30 patients who were treated with intravesical HA-CS, 13 had recurrent UTIs (more than three microbio- logically proven infections in the previous 6 mo) despite lifestyle optimization and conservative treatments. Patients had a mean age of 48 yr, a PUF score of 22, and had had 6.4 UTI episodes in 12 mo. At the end of treatment, 9 of the 13 patients were infection free (the longest for 6 mo), 3 were improved, and 1 discontinued treatment [37] . The remaining 17 patients had IC/PBS (mean 15 voids per day, mean VAS pain score of 6.4, and mean PUF score of 23.4) ( Fig. 6 ), and all received 6 units of HA-CS. The longest follow-up was 6 mo, by which time pain scores were less than half the baseline score, and the PUF score was reduced [(Fig._6)TD$FIG] Fig. 6 – Efficacy of intravesical sodium hyaluronate–chondroitin sulfate in 17 patients with interstitial cystitis/painful bladder syndrome, treated in a district general hospital in Reading, UK [37] . PUF = Pelvic Pain and Urinary/Frequency (score); VA = visual analog (scale score). E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 457 </p>
                                        
                                            <p>8. described previously. HA-CS reduced the increase in MF prompted by the KCl challenge, in seven of nine rats. The increase in this parameter for the PS plus KCl/vehicle (22.0  4.70 micturitions/h; n = 11) versus the control group (9.5  2.27 micturitions/h; n = 10) was significant ( p &lt; 0.05), as expected, but the increase was less, and not significant, in the PS plus KCl/HA-CS group (16.3  4.33 micturitions/h; n = 9). During the posttreatment KCl challenge, treatment with HA-CS did not improve BC, but it was associated with a lower ( p &lt; 0.05) ThP than that in the PS plus KCl/vehicle group ( Fig. 2 ). Interestingly, bladder compliance was improved in the PS plus KCl/HA-CS group because the KCl challenge significantly reduced the value for this parameter in the PS plus KCl/vehicle group but not in the PS plus KCl/HA-CS group ( Fig. 2 ) [25] . In summary, this model demonstrated that only with repeated dosing did HA-CS counteract the increase of MF and ThP following urothelial damage induced by PS plus KCl. Repeat dosing with HA-CS also improved bladder compliance, similar to the effect of the active metabolite of fesoterodine in a different model of bladder overactivity in rats [26] . A similar increase in bladder compliance was reported following systemic administration of another antimuscarinic, namely oxybutinin, in normal rats [27] . The results of our experimental study correlate with clinical studies in patients with BPS that show the effects of HA-CS are evident only with repeat dosing (IBSA Institut Biochimique, unpubl. data). Moreover, because antimuscarinic efficacy in patients seems to be related to an inhibitory effect on the urothelium, decreasing afferent signaling [28] , we can speculate that the increase of bladder compliance observed with intravesical HA-CS in this rat model could be due to an inhibition of bladder afferents, similar to what was observed following systemic oxybutynin in rats [27] . 5.    Clinical use of intravesical sodium hyaluronate– chondroitin sulfate A combination of sodium hyaluronate and chondroitin sulfate is commercially available as a 50-ml intravesical instillation containing sodium hyaluronate 1.6% wt/vol and chondroitin sulfate 2% wt/vol with calcium chloride in water (HA-CS; Ialuril 1 ; IBSA Institut Biochimique SA, Lugano, Switzerland). Both active components of HA-CS are GAGs, which may replace or restore the injured or deficient GAG layer of the urothelium. The notion of a defective GAG barrier is thought to be associated with the pathogenesis of many bladder conditions, including UTIs, IC/BPS, idiopathic detrusor overactivity, calculi, chemical or radiation cystitis, and bladder cancer, and as such may provide alternative approaches to the treatment of those diseases [4,29] . HA-CS reduces the production of proinflammatory cytokines, reduces urothelial permeability, and facilitates the repair of the protective GAG layer [30] . It is indicated in a range of clinical conditions that originate from damage to the GAG layer [2,4] . [(Fig._1)TD$FIG] Fig. 1 – Experimental protocol for repeated treatment with sodium hyaluronate–chondroitin sulfate (HA-CS) in an animal bladder model [25] . KCl = potassium chloride; PS = protamine sulfate; s.c. = subcutaneous. E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 454 </p>
                                        
                                            <p>7. stimuli) and hyperalgesia (exaggerated pain response to mildly painful stimuli) [19,21] . As a consequence of hypersensitivity, there is nonresolved acute trauma, chronic tissue hypoxia, and inflammation, which lead to sensory nerve stimulation [20] . It is hypothesized that the CNS receives an increased afferent barrage from the stimulated peripheral nocicep- tors, triggering central mechanisms that amplify and perpetuate the effect of the peripheral sensory nerve input [21] . All this is considered to lead to the windup phenome- non, which describes profound genetic and phenotypic changes in the CNS, resulting in central sensitization [19] . 2.4.    Early treatment crucial Within 24 h, the stimulated peripheral nociceptors trigger transcriptional factor (eg, C-jun, C-fos, and nuclear factor [NF]-kB) activation, resulting in neuronal growth. Chronic inflammation is associated with an increased production of nerve growth factor and glutamate, enhancing the DNA transcription process and resulting in an increased synthe- sis of neuropeptides. These in turn induce neurogenic inflammation, which is mediated by capsaicin-sensitive fibers. Nerve resprouting follows, as an increase in synaptic craniocaudal and latero-lateral connections [5] . It is clear that once these mechanisms are triggered, any intervention is beset with difficulties and a risk of failure because the inflammatory cascade and hypersensitization is a complex process. Early treatment may be crucial to prevent gene activation and to block the hypersensitivity cycle before it gets going [5] . Protecting the urothelium and preventing bladder lining damage would seem like a logical way of averting the inflammatory processes that further injure the lining and lead to chronic bladder pathologies. 2.5.    Target glycosaminoglycan layer As discussed, urothelial damage is the first step in the cascade of inflammatory processes, which, when triggered, may become chronic. The GAG layer provides the initial barrier for physiologic protection, but once injured or defective, it loses its barrier properties, becomes permeable, and permits the inflammatory and hypersensitization cycle to flourish. Protecting the urothelium or promptly restoring the GAG layer may prevent gene changes in the CNS, which will avert the chronic inflammatory process and pain [5] . 3.    An animal model of the functional effects of urothelial damage An experimental animal model of bladder epithelial dysfunction, based on the potassium sensitivity test, was devised to demonstrate the process and consequences of urothelial damage and for the investigation of treatments to counteract the damage [22,23] . Potassium ions usually present in urine do not affect a healthy bladder lining, but the ions will penetrate and irritate an injured or defective lining [23] . This is the basis of the potassium sensitivity test, which is positive in individuals with certain bladder conditions (namely, urethral syndrome, IC/PBS, chronic pelvic pain, lower urinary tract symptoms, UTIs, detrusor instability, or radiation cystitis) [23] . The experimental model used intravesical instillations of protamine sulfate (PS) and potassium chloride (KCl) in anesthetized female rats. PS is a high molecular weight protein and increases the permeability of the apical mem- brane of the epithelial cells to cations and anions [24] . Ulcerations,irregularitiesin theGAG layer, and anincreasein mastocytes were observed following exposure to intravesical PS [24] . In addition, a continuous infusion of PS and 0.5 M KCl induced bladder hyperactivity, mimicking the urothelial damage (prompted by the PS), and increased bladder activity (resulting from the irritation prompted by the KCl), typical in patients with painful bladder syndrome [22] . This experimental protocol was validated by studying the modifications of cystometric parameters induced by pretreatment of the animal model with PS and KCl intravesically. The following cystometric parameters were evaluated: basal pressure (BP), the intravesical pressure at the end of micturition; threshold bladder pressure (ThP), bladder pressure immediately before micturition; maxi- mum micturition pressure (MaxMP), maximum pressure during micturition; amplitude of micturition (MaxMP minus ThP); intercontraction interval, the time in seconds between two successive micturitions; and bladder compli- ance ( D V/ D P), the ratio of the change in micturition volume to the change in micturition pressure). Intravesical pressure recordings following instillations of physiologic saline for 1 h followed by PS (10 mg/ml) plus 0.5 M KCl for 30 min demonstrated bladder overactivity, as previously described by Chuang et al [22] . These instilla- tions also reduced bladder capacity (BC) and increased micturition frequency (MF), ThP, and BP [22,25] . 4.    Experimental effects of the combination of sodium hyaluronate and chondroitin sulfate in the rat model The effects of intravesical sodium hyaluronate 1.6%– chondroitin sulfate 2% (HA-CS; Ialuril 1 ; IBSA Institut Biochimique SA, Lugano, Switzerland) on bladder hyperac- tivity induced by PS 10 mg/ml and 0.5 M KCl in anesthetized and catheterized rats was investigated via two protocols, the first following a single-dose HA-CS instillation and the second using two HA-CS doses 24 h apart [25] . Physiologic saline/vehicle (sterile water), PS plus KCl/ vehicle and PS plus KCl/HA-CS constituted the interventions and instillation sequences for each group of rats ( n = 9–11), following a basal period of a 1-h instillation of saline into the bladder in all groups. Two groups received consecutive 30-min intravesical instillations of PS and KCl (PS plus KCl), and in one group, an instillation of HA-CS was then kept in contact with the bladder urothelium for 60 min. There were no differences between the PS plus KCl/vehicle and PS plus KCl/HA-CS groups for any cystometric parameters, with the single 60-min intravesical HA-CS treatment [25] . The second protocol ( Fig. 1 ) included two doses of HA-CS 24 h apart according to the same sequence of instillations E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 453 </p>
                                        
                                            <p>6. 1.    Introduction The development of effective treatment for chronic cystitis has been hampered by the lack of general consensus on the origin of this condition [1] . Ongoing, distressing, and often refractory symptoms (dysuria, pelvic pain, urinary frequen- cy and urgency, and nocturia) present a challenge for patients and clinicians alike [2,3] . Hypotheses for the cause of chronic cystitis range from it being an autoimmune condition or an allergy to it stemming from occult infection, exposure to toxins, certain dietary elements, or even psychosomatic factors [1] . Central, however, is the idea of urothelial damage as a trigger for chronic cystitis [3] , and it has been suggested that a wide range of conditions may be characterized by the feature of a leaky urothelium, including interstitial cystitis/painful bladder syndrome (IC/PBS), chemical or radiation cystitis, and recurrent urinary tract infections (UTIs) [4] . 2.    The role of the urinary epithelium in bladder dysfunction Understanding the role of the urothelium in bladder dysfunction may offer the opportunity for new insights into the hitherto fairly cryptic pathogenesis of some chronic and challenging bladder conditions and would pave the way for newer targeted therapies, which clinicians and patients alike would welcome [4,5] . 2.1.    Structure of the urothelium The urothelium, the epithelial lining of the bladder, also known as the transitional epithelium, is not just a simple barrier or nonspecific defense against infection, urinary solutes, or toxins; it is now recognized as a specialized tissue that regulates complex bladder function and plays a fundamental and active role in the pathogenesis of cystitis [4,5] . The surface of the urothelial umbrella cells carries a thick layer of glycoproteins and proteoglycans, together forming a glycosaminoglycan (GAG) layer, which constitutes a hydrophilic mucosal coating and a barrier against solutes or noxious substances in the urine [3] . Other examples of GAGs are hyaluronan in synovial fluid lubricant and chondroitin in connective tissues [6] . The role of this GAG layer in the bladder has recently come into focus because evidence indicates that a defect in this layer may be the first step in the development of chronic inflammatory diseases of the bladder. One of a range of noxious stimuli may underlie the early stage of the GAG layer injury, leading to deficient barrier activity that would be inadequate in warding off further injury. 2.2.    Etiology and pathogenesis of chronic bladder pain The etiology of chronic cystitis is still obscure, and although there is still limited evidence, damage to the urothelium is thought to be central to all these bladder pathologies; the damage may originate from infection, primary neurogenic inflammation, oncology drugs or radiation, bladder trauma or overdistention, pelvic floor dysfunction, or an autoim- mune response [4] . The cascade of events following leakage of urinary constituents (particularly potassium) through the defective urothelium into the interstitium of the bladder wall includes C-fiber activation (substance P released [7] ), mast cell activation, and histamine release [8] . Regardless of the original cause of the injury, the inflammatory process begins and evolves similarly in each case. The urothelium loses its barrier to further assault from typical and abnormal substances (drugs and toxins) excreted in the urine, which then come into contact with the subepithelial layers and trigger deeper inflammation [5] . Decreased GAG production by the urothelium appears to increase the permeability and aggravate the injury, and studies have shown a decreased urinary elimination of GAG in patients with interstitial cystitis [9] . Following injury, the urothelium typically heals via a self- maintaining process, but untreated or unresolved inflamma- tion blocks the spontaneous healing of the GAG layer of the urothelium via secretion by the epithelial cells of an antiproliferative factor [10,11] . In addition, the secretion of prostaglandin E2, which contributes to urothelium repair, has been reported to fade in patients with IC/PBS [12] . More important, there is a change in receptor sensitivity in peripheral organs and nerve tissue, activating genes in the centralnervoussystem(CNS)andleadingtothepossibilityof chronic neuropathic pain [13–16] . This sequence of events explains why delayed therapy usually fails and the condition becomes chronic [5] . 2.3.    Not just a simple inflammatory process What actually happens? Urothelial damage prompts C-fiber activation, causing smooth muscle contraction, neurogenic inflammation, and hypersensitivity [5,17] . For the patient, this means urinary urgency and frequency and chronic pelvic pain, which are the features of, amongst other bladder conditions, overactive bladder syndrome and/or painful bladder syndrome [18] . Neurogenic inflammation is a result of pathologic activation of primary sensory nerves (C-fibers), which have a characteristic ‘‘afferent/efferent’’ double/dual function. The afferent function is involved in control of the micturition reflex, pain transmission, and cardiovascular reflex modula- tion, whereas the efferent function is linked to the release of substance P [7] , calcitonin gene-related peptide (CGRP) and tachykinins, which produce the smooth muscle contraction characteristic of overactive bladder syndrome. The efferent function is also responsible for immuno-cell migration, mast cell degranulation, and extravasation, contributing to pain [7] . This neurogenic inflammation is hypothesized to be the source of the visceral hypersensitivity from which chronic pelvic pain is derived [19,20] . It has been suggested that, more often than not, chronic bladder pain is not just due to a simple inflammatory process but is related to hypersensi- tivity, which features allodynia (painful response to normal E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 452 </p>
                                        
                                            <p>10. identified pathogen] in the last year and with clinical symptoms). Patients in the treatment group ( n = 28) received a 50-ml intravesical instillation of HA-CS weekly for 4 wk and then monthly for 5 mo. Patients in the control group ( n = 29) received a saline instillation according to the same schedule [32] . At 12 mo, HA-CS recipients experienced an almost 90% reduction in the mean rate of UTIs per patient per year versus a 10% reduction for the control group (86.6%  47.6 vs 9.6%  24.6; p = 0.0002), and they lasted approximately 3.5-fold longer between episodes compared with the control group (mean time to UTI recurrence 185.2  78.7 versus 52.7  33.4 d; p &lt; 0.001) ( Fig. 3 ). In addition, symptoms assessed by the Pelvic Pain and Urinary/Frequency (PUF) questionnaire and quality-of-life assessed by the SF-36 Quality-of-Life (QOL) questionnaire improved significantly more with HA-CS than with placebo (PUF score: 14.53  4.32 vs 9.88  6.77 [ p = 0.004]; SF-36 QOL score 78.6  6.44 vs 53.1  4.72 [ p &lt; 0.001]) [32] . Damiano et al concluded: ‘‘Effective and safe strategies to prevent recurrent UTI that avoid the use of antimicrobials are highly desirable. Our findings show the efficacy of a bladder instillation of combined HA-CS in preventing UTI in this study population’’ [30,32] . 5.2.    Interstitial cystitis/painful bladder syndrome An open-label study by Cervigni et al of intravesical instillations of HA-CS (weekly for 20 wk and monthly for 3 mo) in 23 female patients with refractory IC/PBS demon- strated an improvement in bladder function and a reduction inurinarysymptoms [2] .IC/PBSischaracterizedbyurothelial damage leading to urinary frequency/urgency and pelvic pain,andthe conditionfrequentlyisorbecomesrefractoryto therapy [2] . Patients treated with intravesical HA-CS experienced a reduction from baseline in the daily number of voids, an increase in the mean voiding volume, and a reduction in visual analog scale (VAS) scores for pain, frequency, and urgency [2] ( Fig. 4 ). QOL data indicated improvements in symptom and problem index scores on the O’Leary-Sant questionnaire, and symptom, bother, and total scores on the PUF Symptom Scale scores for HA-CS recipients [2] ( Fig. 5 ). 5.3.    Urinary calculi The use of exogenous GAG therapy with HA-CS for calculi may be a logical choice because GAGs are present on all surfaces of the urinary tract and have been shown [(Fig._4)TD$FIG] Fig. 4 – Urinary function parameters in patients with interstitial cystitis/ painful bladder syndrome receiving intravesical sodium hyaluronate– chondroitin sulfate [2] . VAS = visual analog scale. [(Fig._5)TD$FIG] Fig. 5 – Quality-of-life assessments in patients with interstitial cystitis/ painful bladder syndrome receiving intravesical sodium hyaluronate– chondroitin sulfate [2] . E U R O P E A N U R O L O G Y S U P P L E M E N T S 1 0 ( 2 0 1 1 ) 4 5 1 – 4 5 9 456 </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1384</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1039</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">345</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">22</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">13</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1462 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1302 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1360 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1297 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1412 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1366 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/30/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1219 Views . <timeago class="timeago" datetime="2019-10-31 13:38:52.835202"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1386 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1249 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="96fff8f0f9d6fef4e5b8fee3">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/glycosaminoglycan-therapy-for-bladder-diseases-22 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:03:42 GMT -->
</html>
    
    
